Premium
Simultaneous determination of paracetamol and dextropropoxyphene in human plasma by liquid chromatography/tandem mass spectrometry: application to clinical bioequivalence studies
Author(s) -
Yin Ophelia Q. P.,
Lam Sherry S. L.,
Chow Moses S. S.
Publication year - 2005
Publication title -
rapid communications in mass spectrometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.528
H-Index - 136
eISSN - 1097-0231
pISSN - 0951-4198
DOI - 10.1002/rcm.1850
Subject(s) - propoxyphene , chemistry , chromatography , tolbutamide , bioequivalence , mass spectrometry , liquid chromatography–mass spectrometry , acetic acid , mefenamic acid , analgesic , pharmacokinetics , pharmacology , medicine , diabetes mellitus , biochemistry , endocrinology
A liquid chromatography/mass spectrometry method for simultaneous determination of paracetamol and dextropropoxyphene in human plasma is described. Paracetamol and dextropropoxyphene, together with their internal standards (tolbutamide and pyrroliphene), were extracted from 0.5 mL of plasma using solid‐phase extraction. The chromatography was performed using a Thermo Hypersil APS‐2 Amino column (250 mm × 4.6 mm, 5 μm) with a mobile phase consisting of acetonitrile and 0.4% glacial acetic acid in water (20:80). The total run time was 6 min for each sample. The triple‐quadrupole mass spectrometer was operated in both positive (for detection of dextropropoxyphene and its IS pyrroliphene) and negative (for detection of paracetamol and its IS tolbutamide) modes using a polarity‐switching technique. Multiple reaction monitoring was used for quantification. The method was linear over the concentration range of 0.1–20 μg/mL for paracetamol and 0.5–80 ng/mL for dextropropoxyphene. The intra‐ and inter‐day precision were less than 10%, and the accuracy ranged from 92.2–110.9%. The lower limits of quantification were 0.1 μg/mL for paracetamol and 0.5 ng/mL for dextropropoxyphene. The present method provides a robust, fast and sensitive analytical tool for both paracetamol and dextropropoxyphene, and has been successfully applied to a clinical bioequivalence study in 14 subjects. Copyright © 2005 John Wiley & Sons, Ltd.